Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of "Buy" by Brokerages

Shares of Genelux Co. (NASDAQ:GNLX - Get Free Report) have earned a consensus recommendation of "Buy" from the five brokerages that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $17.75.

Several research analysts recently commented on GNLX shares. Wall Street Zen cut Genelux from a "hold" rating to a "sell" rating in a research report on Friday. Benchmark reduced their target price on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Genelux in a research report on Monday, March 31st.

Genelux Stock Performance

NASDAQ:GNLX opened at $2.56 on Friday. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89. The stock's 50 day moving average price is $2.55 and its 200 day moving average price is $3.06. The company has a market capitalization of $96.60 million, a P/E ratio of -2.69 and a beta of -0.49.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. As a group, sell-side analysts forecast that Genelux will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Genelux

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Woodward Diversified Capital LLC increased its position in Genelux by 15.2% in the first quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company's stock worth $3,945,000 after purchasing an additional 192,808 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Genelux during the 1st quarter worth about $770,000. Heights Capital Management Inc. acquired a new position in shares of Genelux during the 1st quarter worth about $644,000. Marshall Wace LLP grew its position in shares of Genelux by 51.4% during the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after buying an additional 52,958 shares during the period. Finally, LPL Financial LLC grew its position in shares of Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after buying an additional 39,516 shares during the period. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.